Arbutus Biopharma Corp
ABUSFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Arbutus Biopharma Corp Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 15 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 10, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Independent insiders buying near the same time
- 2018-01-12–2018-01-12: 8 event(s) across 8 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing , filing )
- 2017-10-16–2017-10-16: 8 event(s) across 8 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2025-02-04 | Naftzger J. Christopher · General Counsel and CCO | Common Shares | S — Open market or private sale | −11,333 | 3.28 | SEC filing |
| 2025-02-04 | McElhaugh Michael J. · Interim President & CEO | Common Shares | S — Open market or private sale | −23,790 | 3.28 | SEC filing |
| 2025-02-04 | HASTINGS DAVID C · Chief Financial Officer | Common Shares | S — Open market or private sale | −22,183 | 3.28 | SEC filing |
| 2025-02-04 | Sims Karen · Chief Medical Officer | Common Shares | S — Open market or private sale | −19,348 | 3.28 | SEC filing |
| 2024-08-14 | MANCHESTER KEITH S · Director | Common Shares | S — Open market or private sale | −8,846 | 3.69 | SEC filing |
| 2024-02-02 | HASTINGS DAVID C · Chief Financial Officer | Common Shares | S — Open market or private sale | −9,593 | 2.31 | SEC filing |
| 2024-02-02 | McElhaugh Michael J. · Interim President & CEO | Common Shares | S — Open market or private sale | −10,164 | 2.31 | SEC filing |
| 2024-02-02 | Sims Karen · Chief Medical Officer | Common Shares | S — Open market or private sale | −4,358 | 2.31 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-08 | Sawhney Roger · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +78,800 | SEC filing |
| 2026-06-08 | Beardsley Robert A · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +78,800 | SEC filing |
| 2026-02-02 | Nguyen Tuan · Chief Financial Officer | Common Shares | A — Grant, award, or other acquisition | +73,500 | SEC filing |
| 2026-02-02 | Nguyen Tuan · Chief Financial Officer | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +188,400 | SEC filing |
| 2026-02-02 | Androski Lindsay · President and CEO | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +71,700 | SEC filing |
| 2026-02-02 | Androski Lindsay · President and CEO | Common Shares | A — Grant, award, or other acquisition | +28,000 | SEC filing |
| 2025-08-04 | Sawhney Roger · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +157,600 | SEC filing |
| 2025-03-31 (amended) | Nguyen Tuan · Chief Financial Officer | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +750,000 | SEC filing |
Showing 8 of 20 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.